Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Part of paid clinical trials in Seattle, Washington.

Sponsor
Fred Hutchinson Cancer Center
Study ID
NCT00217529
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving erlotinib together with docetaxel and carboplatin may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when given together with docetaxel and carboplatin and to see how well they work in treating patients with newly diagnosed stage III or stage IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer.

Key Dates

First listed
Sep 22, 2005
Start date
Jun 30, 2004
Status verified
Sep 2010
Primary completion
Nov 30, 2005

Study Design

Primary purpose
TREATMENT

Primary Outcome Measure

Maximum tolerated dose of erlotinib

Locations (3)

FacilityCityStateZIPSite coordinators
Fred Hutchinson Cancer Research CenterSeattleWashington98109-1024-
Pacific Gynecology SpecialistsSeattleWashington98104-
University of Washington School of MedicineSeattleWashington98195-

Find similar trials in Seattle, WA

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Fred Hutchinson Cancer Research Center· Seattle, WAPacific Gynecology Specialists· Seattle, WAUniversity of Washington School of Medicine· Seattle, WA

Related Studies